https://doi.org/10.4081/aiua.2025.13615
Increased expression of transglutaminase-2 is associated with invasive disease in bladder cancer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2025
Purpose: Transglutaminase-2 is associated with tumor invasion, metastasis development, chemoresistance and poor prognosis in various cancer types. In this study, our aim was to show the association between increased transglutaminase-2 expression and the invasive pattern of bladder cancer. Materials and methods: Tumor tissues from eighty-eight patients with bladder cancer (43 muscle-invasive, 45 non-muscle invasive bladder cancer) were immunohistochemically evaluated for TG2 expression.
Results: Transglutaminase-2 expression score was higher in muscle- invasive bladder cancer compared to non-muscle invasive bladder cancer tissues (5.37±1.5 vs 0.71±1.4, p<0.001). No statistically significant difference was found in transglutaminase- 2 expression scores between metastatic and non-metastatic disease in MIBC group. Different tumor and lymphnode stages in MIBC were also found to be not correlated with transglutaminase- 2 expression scores.
Conclusions: The over-expression of transglutaminase-2 is associated with invasive disease in bladder cancer. According to our results, transglutaminase-2 has the potential to be useful for predicting the invasion in bladder cancer and addressing treatment.
Downloads
Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020; 38:1895-1904. DOI: https://doi.org/10.1007/s00345-019-02984-4
Shariat SF, Sfakianos JP, Droller MJ, et al. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010; 105:300-308. DOI: https://doi.org/10.1111/j.1464-410X.2009.09076.x
Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013; 63:234-41. DOI: https://doi.org/10.1016/j.eururo.2012.07.033
Siregar GP, Parwati I, Noegroho BS, et al. The association between serum hypoxia inducible factor-1α level and urothelial bladder cancer: A preliminary study. Arch Ital Urol Androl. 2023; 95:11292. DOI: https://doi.org/10.4081/aiua.2023.11292
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020; 324:1980-1991. DOI: https://doi.org/10.1001/jama.2020.17598
Odii BO, Coussons P. Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family. ScientificWorldJournal. 2014; 2014:714561. DOI: https://doi.org/10.1155/2014/714561
Tabolacci C, De Martino A, Mischiati C, et al. The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression. Med Sci (Basel). 2019; 7:19. DOI: https://doi.org/10.3390/medsci7020019
Malkomes P, Lunger I, Oppermann E, et al. Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a
therapeutic target. Cancer Gene Ther. 2023; 30:1346-1354. DOI: https://doi.org/10.1038/s41417-023-00641-y
Chang W, Gao W, Liu D, et al. The upregulation of TGM2 is associated with poor prognosis and the shaping of the inflammatory tumor microenvironment in lung squamous cell carcinoma. Am J Cancer Res. 2024; 14:2823-2838. DOI: https://doi.org/10.62347/OBES4130
Buccarelli M, Castellani G, Fiorentino V, et al. Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors. Cells. 2024; 13:667. DOI: https://doi.org/10.3390/cells13080667
Verma A, Wang H, Manavathi B, et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its
implications in drug resistance and metastasis. Cancer Res. 2006;66:10525-10533. DOI: https://doi.org/10.1158/0008-5472.CAN-06-2387
Shao M, Cao L, Shen C, et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res. 2009; 69:9192-9201. DOI: https://doi.org/10.1158/0008-5472.CAN-09-1257
Cao L, Shao M, Schilder J, et al. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012; 31:2521-2534 DOI: https://doi.org/10.1038/onc.2011.429
Eckert RL, Kaartinen MT, Nurminskaya M, et al. Transglutaminase regulation of cell function. Physiol Rev. 2014;94:383-417. DOI: https://doi.org/10.1152/physrev.00019.2013
Erdem S, Yegen G, Telci D, et al. The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma. World J Urol. 2015; 33:1553-1560. DOI: https://doi.org/10.1007/s00345-014-1462-7
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890. DOI: https://doi.org/10.1016/j.cell.2009.11.007
Chen X, Adhikary G, Newland JJ. et al. Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype. Mol. Cancer Res. 2023; 21:922-932. DOI: https://doi.org/10.1158/1541-7786.MCR-23-0051
Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715. DOI: https://doi.org/10.1016/j.cell.2008.03.027
Kumar A, Gao H, Xu J, et al. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011; 6:e20701. 20. Shinde A, Kulkoyluoglu Cotul E, Chen H, et al. Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer. Mol Biomed. 2022; 3:19. DOI: https://doi.org/10.1371/journal.pone.0020701
Li M, Wang X, Hong J, et al. Transglutaminase 2 in breast cancer metastasis and drug resistance. Front Cell Dev Biol. 2024;12:1485258. DOI: https://doi.org/10.3389/fcell.2024.1485258
Fernández-Aceñero MJ, Torres S, Garcia-Palmero I, et al. Prognostic role of tissue transglutaminase 2 in colon carcinoma. Virchows Arch. 2016; 469:611-619. DOI: https://doi.org/10.1007/s00428-016-2020-z
Kang S, Oh SC, Min BW, Lee DH. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells. Anticancer Res. 2018; 38:787-794. DOI: https://doi.org/10.21873/anticanres.12285
Condello S, Prasad M, Atwani R, Matei D. Tissue transglutaminase activates integrin-linked kinase and β-catenin in ovarian cancer. J Biol Chem. 2022; 298:102242. DOI: https://doi.org/10.1016/j.jbc.2022.102242
Chihong Z, Yutian L, Danying W, et al. Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients. Oncotarget. 2017; 8:45577-45584 DOI: https://doi.org/10.18632/oncotarget.17374
Huaying S, Dong Y, Chihong Z, et al. Transglutaminase 2 Inhibitor KCC009 Induces p53-Independent Radiosensitization in Lung Adenocarcinoma Cells. Med Sci Monit. 2016; 22:5041-5048. DOI: https://doi.org/10.12659/MSM.901605
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.